Massive Bio

We're expanding access to oncology clinical trials for underserved communities, with privacy built in from the start. Massive Bio has deployed its AI-powered pre-screening capabilities through BeeKeeperAI's EscrowAI® platform, leveraging federated confidential computing to match cancer patients to clinical trials without ever moving their sensitive data outside the healthcare provider's environment. The program initially focuses on the #Atlanta, #Georgia region, working to reach historically underrepresented patient populations who may otherwise never learn about trials they qualify for. This is what equitable, scalable clinical research looks like: AI traveling to the data, not the other way around. 🔗 Read the full announcement: https://lnkd.in/ddJXP-Nq Selin Kurnaz, PhD | Arturo LoAIza-Bonilla MD | Çağatay M. Çulcuoğlu

Our Co-Founder, CTO & COO Çağatay M. Çulcuoğlu and Director of OUS Provider Engagement Mert Sari attended DataForum in #Mainz, joining researchers, clinicians, legal experts, and data infrastructure professionals for an afternoon of substantive discussions on responsible health data use in Europe. As Massive Bio continues to grow its presence in Germany and across the DACH region, events like DataForum are an important part of how we engage with the ecosystem, from data governance and the EU Health Data Space to real-world evidence and clinical research infrastructure. These are conversations that directly inform how we build and scale our AI-driven clinical trial matching platform. Thank you IDG Institut für digitale Gesundheitsdaten RLP for bringing the right people into the same room. #DataForum #HealthData #DigitalHealth #RealWorldData #Germany Selin Kurnaz, PhD | Arturo LoAIza-Bonilla MD | Çağatay M. Çulcuoğlu

Germany, we're here. 🇩🇪 Our Co-Founder, CTO & COO Çağatay M. Çulcuoğlu is at DataForum today in #Mainz, joining researchers, clinicians, lawyers, and data infrastructure experts for a full afternoon of talks and hands-on exchange around one of healthcare's most pressing challenges: turning health data into real-world impact. From the EU Health Data Space to real-world evidence, data governance to clinical research infrastructure, the conversations happening today matter deeply to what we build at Massive Bio every day. See you at KUZ. 👋 📅 May 19 | KUZ – Kulturzentrum Mainz, Germany #DataForum #HealthData #DigitalHealth #RealWorldData Selin Kurnaz, PhD | Arturo LoAIza-Bonilla MD | Çağatay M. Çulcuoğlu IDG Institut für digitale Gesundheitsdaten RLP

Our Co-Founder, CTO & COO Çağatay M. Çulcuoğlu will be at the OncoInnovate Europe Conference 2026 in #Vienna on May 21, joining a panel discussion on "Transforming Oncology & Cancer Care Through AI and Intelligent Systems." Çağatay will be speaking on AI-Powered Navigation of Care Pathways, Precision Oncology & Clinical Trials, a topic that sits at the heart of what Massive Bio does every day across 17+ countries. The panel brings together leaders from across the oncology and health innovation ecosystem to explore how AI and data are reshaping cancer care at every level, from virtualized biological experiments to national oncology systems. Taking place as part of #ViennaUp, with participants from #Germany, #Austria, and across #Europe, these are the conversations pushing the field forward. Proud to have our Co-Founder at the table. #OncologyInnovation #OncoInnovate2026 #PrecisionOncology #ClinicalTrials #AIinOncology #ViennaUp Selin Kurnaz, PhD | Arturo LoAIza-Bonilla MD | Çağatay M. Çulcuoğlu

Our Co-Founder and CEO Selin Kurnaz, PhD was in #Nashville for the AGC Partners HCIT & Life Sciences Technology Summit, with 16 investor meetings in a single day. The investment landscape for healthcare AI is shifting. Traditional software models are being re-evaluated, consolidation is on the horizon, and the platforms that own a vertical with direct patient-consented data at their core are the ones positioned to lead. Massive Bio is at the center of that shift. Hear Selin's take on what investors are signaling and what it means for the road ahead, and visit massivebio.com/asco26 to see what Massive Bio is bringing to #ASCO2026 and schedule a meeting. #HealthcareAI #Oncology #ClinicalTrials #HealthTech #PrecisionOncology #ASCO2026 #ASCO26 Selin Kurnaz, PhD | Arturo LoAIza-Bonilla MD | Çağatay M. Çulcuoğlu

Massive Bio and Just Worldwide are partnering to connect more cancer patients to clinical trial opportunities, through patient communities, advocacy groups, and AI-driven trial matching. Only 3–5% of cancer patients ever enroll in a clinical trial. The barrier is rarely eligibility. It is awareness, access, and trust. Just Worldwide brings deep engagement with patient communities, including underrepresented populations, at a scale that traditional recruitment methods cannot reach. Massive Bio brings the AI infrastructure to match those patients to the right trials at the right moment. Together, we are closing the gap between patients who qualify and trials that need them. "As oncologists, we know that the right clinical trial can be a turning point for a patient, but only if they know it exists. Just Worldwide's ability to engage patients and advocacy communities at scale, combined with Massive Bio's AI matching engine, creates a system where the right information finds the right patient at exactly the right moment in their journey." — Arturo LoAIza-Bonilla MD, Co-Founder & Chief Medical AI Officer, Massive Bio 🔗 Read the full press release: https://lnkd.in/dFycWj-t #ClinicalTrials #Oncology #AIinOncology #CancerCare #PatientAccess #HealthEquity #PrecisionOncology Selin Kurnaz, PhD | Arturo LoAIza-Bonilla MD | Çağatay M. Çulcuoğlu

Grateful to be a sponsor of #DHAI2026 in Boston this June. The conversation in oncology has shifted. It's no longer about whether AI can help, it's about how fast we can deploy it where it matters most: at the patient level. At Massive Bio, that's exactly what we're building. AI-powered matching that gives cancer patients access to clinical trials they'd otherwise never know about. Looking forward to connecting with leaders who share the same urgency in Boston, June 8–9. #AIinHealthcare #PrecisionOncology #ClinicalTrials #DigitalHealth Selin Kurnaz, PhD | Arturo LoAIza-Bonilla MD | Çağatay M. Çulcuoğlu Digital Health & AI Innovation Summit (DHAI)

Massive Bio was featured in Genetic Engineering & Biotechnology News as part of a deep dive into how AI is reshaping drug discovery and clinical research. The piece covers a broader shift: big tech is building AI platforms purpose-built for scientific workflows. The inference inflection has arrived in biopharma. For us, this reinforces what we've been building, AI-driven infrastructure that matches cancer patients to clinical trials with the speed and rigor oncology demands. 🔗: https://lnkd.in/g69wFtpt Selin Kurnaz, PhD | Arturo LoAIza-Bonilla MD | Çağatay M. Çulcuoğlu

What does it actually take to rewire health delivery at scale, not just regionally, but globally?   Our Co-Founder & Chief Medical AI Officer, Dr. Arturo LoAIza-Bonilla MD, joined Fern Lazar at the 1BusinessWorld Global Health & Purpose Summit to tackle exactly that.   In their session "From Innovation to Impact: Rewiring Global and Regional Health Delivery at Scale," Arturo and Fern explored how AI-driven precision oncology is bridging the gap between breakthrough innovation and real-world patient outcomes, across borders, healthcare systems, and clinical realities.   At Massive Bio, that's not a vision statement. It's what we build every day.   🎥 Watch the full session → https://lnkd.in/d7c2BgYS   #GlobalHealth #PrecisionOncology #HealthcareAI #ClinicalTrials #Innovation Selin Kurnaz, PhD | Arturo LoAIza-Bonilla MD | Çağatay M. Çulcuoğlu

Our Project Manager Arjin Dursun recently joined the Nursing Department at Medipol University for a talk titled "Nursing in Clinical Research: From the Field to Project Management." Arjin shared insights from her journey at Massive Bio on the evolving role of nursing in clinical research, and how medical knowledge, combined with technology and AI, drives meaningful patient outcomes. From trial management to customer success, it was a valuable exchange with the next generation of clinical professionals. #ClinicalResearch #Nursing #AIinHealthcare #PrecisionOncology #ClinicalTrials Selin Kurnaz, PhD | Arturo LoAIza-Bonilla MD | Çağatay M. Çulcuoğlu